Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (436)	5/15/2000 1:14:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

From 1Q 10Q file: o Cytokine Traps: Protein-based antagonists for cytokines such as interleukin-1 (called IL-1), interleukin-4 (IL-4), interleukin-6 (IL-6) and a single antagonist that blocks both IL-4 and interleukin-13 (IL-13). These cytokines are thought to play a major role in diseases such as rheumatoid arthritis and other inflammatory diseases, asthma, allergic disorders, and cancer. Cytokine Traps are potential treatments for these diseases, and at least one Cytokine Trap is expected to enter clinical trials by 2001. o VEGF Trap: An antagonist to Vascular Endothelial Growth Factor (called VEGF), which is required for the growth of blood vessels that are needed for tumors to grow. In a preclinical model of cancer, the VEGF Trap blocked the growth of tumors by an anti-angiogenesis mechanism. VEGF Trap is a potential treatment for cancer and is expected to enter clinical trials in 2001. o Angiopoietins: A new family of growth factors, discovered by us, that are specific for blood vessels and early hemopoietic stem cells. The Angiopoietins, and engineered forms of these growth factors that can act as activators and blockers, are in preclinical testing for promoting blood vessel growth (to provide blood flow in diseased hearts and other tissues that have lost their original blood supplies), for blocking blood vessel growth (for the treatment of cancers), for fixing leaky blood vessels (that cause swelling and edema in many different diseases such as stroke, diabetic retinopathy, and inflammatory diseases), and for promoting the growth and mobilization of certain hemopoietic cells such as stem cells and platelets. ...A multi-center study of more than 300 ALS patients who will receive BDNF subcutaneously began in August 1999 and is fully enrolled. ...In February 2000, Regeneron initiated a double-blind, placebo-controlled Phase II study in more than 100 patients with functional constipation. Again delay in trap IND, while good progress with VEGF trap (push from P&G). BDNF trial fully enrolled. Hope this time outcome will be positive. Miljenko

To: Miljenko Zuanic who wrote (436)	5/28/2000 4:29:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

RE: Short interest confusion!!! <<However, based on increased short position for last month, some investors do not think some. This may be part of the price stabilization (read deflation, by certain underwriters) before secondary. Soon or later they will cover their positions.>> While short interest for May show increase of 93K from 98K(95%): "REGN",190661,97825,92836,95,178311, based on April short report of 1440K, it is down in May: "REGN",1440175,163234,1276941,782,548788 Someone did manipulate stock price during secondary and make quick nice profit. Wandering when will SEC crack down on this activity type and protect small investors! Miljenko